---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-113362"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2025-09-08T23:59:59+00:00"
generated_at: "2026-05-17T07:34:55.576772+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical receives additional $3M from Healthcare Royalty; reduces royalty cap

## Summary
- Company entered Omnibus Amendment with Healthcare Royalty Partners; received $3.0M for remaining SCS Microinjector assets.
- Royalty threshold for expiration reduced from $110.5M to $106.5M; potential lower future payments.
- Purchaser waived right to foreclose on Seller capital stock in specified circumstances.
- All other terms of original 2022 Purchase/Sale and Contribution Agreements remain unchanged.

## SEC filing metadata
- accession: 0000950170-25-113362
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2025-09-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017025113362/0000950170-25-113362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017025113362/clsd-20250904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-113362
- JSON: https://secwatch.observer/filing/0000950170-25-113362.json
- Plain text: https://secwatch.observer/filing/0000950170-25-113362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.